Biopharmaceutical company Gilead Sciences recently announced a renewed partnership with KSA-based Cigalah Healthcare and expansion plans to advance patient care and access to medicine in Saudi Arabia through 2026.
The agreement includes a comprehensive distribution arrangement, with Cigalah Healthcare securing distribution rights for Gilead products across its various therapeutic areas.
Earlier this year, Gilead established and launched its fully operational affiliate in the Kingdom, Gilead Sciences Arabia, to enable direct access to healthcare providers and enhance patient support.
Vitor Papao, General Manager of Gilead Sciences, Middle East, commented: “Our ongoing partnership with Cigalah Healthcare is integral to our mission of expanding access to innovative treatments in the Kingdom. This is closely in line with Vision 2030, where the healthcare sector is undergoing transformation to meet the needs of every member of the society. Through our renewed agreement, we are well positioned to leverage Cigalah’s extensive network to reach even more patients.”
Vitor Papao, General Manager of Gilead Sciences, Middle East
Yasser Yousuf Naghi, CEO of Cigalah, stated: "Gilead is a global leader in innovative pharmaceutical solutions for Virology, Infectiology, and Oncology. For Cigalah, this partnership offers the opportunity to gain valuable expertise in highly specialised and innovative therapy areas, to ultimately contribute towards the realisation of the Health Sector Transformation Program and serve our community."
Gilead reaffirms its commitment and continuous efforts to become an integrated partner in the regional healthcare sector, aligning with ambitious national visions for the realisation of healthcare goals. The renewal of this partnership underscores the company's dedication and is another step towards building a healthier future for all involved.
